transe20210105

0001437749-21-000199.txt : 20210106 0001437749-21-000199.hdr.sgml : 20210106 20210106070326 ACCESSION NUMBER: 0001437749-21-000199 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210106 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210106 DATE AS OF CHANGE: 20210106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSENTERIX, INC. CENTRAL INDEX KEY: 0000876378 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 112962080 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19437 FILM NUMBER: 21508981 BUSINESS ADDRESS: STREET 1: 635 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-765-8400 MAIL ADDRESS: STREET 1: 635 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: TRANSENTERIX INC. DATE OF NAME CHANGE: 20131210 FORMER COMPANY: FORMER CONFORMED NAME: SafeStitch Medical, Inc. DATE OF NAME CHANGE: 20080211 FORMER COMPANY: FORMER CONFORMED NAME: CELLULAR TECHNICAL SERVICES CO INC DATE OF NAME CHANGE: 19930328 8-K 1 transe20210105_8k.htm FORM 8-K transe20210105_8k.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

January 6, 2021
Date of Report (date of earliest event reported)

_________________

TransEnterix, Inc.

(Exact name of Registrant as specified in its charter)

_________________

Delaware

(State or other jurisdiction of

incorporation or organization)

0-19437

(Commission

File Number)

11-2962080

(I.R.S. Employer
Identification Number)

635 Davis Drive, Suite 300
Morrisville, North Carolina 27560
(Address of principal executive offices)

919-765-8400
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

_________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock $0.001 par value per share		TRXC		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 6, 2021, TransEnterix, Inc., a Delaware corporation (the “Company”), issued a press release announcing an update with preliminary financial results for the fourth quarter and full year ended December 31, 2020.

A copy of the press release is filed herewith as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit

Exhibit No.	Description

99.1	Press release dated January 6, 2021

104	Cover Page Interactive Data File (formatted in inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRANSENTERIX, INC.

Date: January 6, 2021	/s/ Shameze Rampertab
	Shameze Rampertab Executive Vice President and Chief Financial Officer

EX-99.1 2 ex_219892.htm EXHIBIT 99.1 ex_219892.htm

Exhibit 99.1

TransEnterix Provides Preliminary 2020 Year-End Corporate Update

January 6, 2021

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jan. 6, 2021-- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today provided a preliminary 2020 year-end corporate update.

Recent Highlights

●

Senhance® Surgical System received its registration certificate by the Russian medical device regulatory agency, Roszdravnadzor, allowing for its sale and utilization throughout the Russian Federation

●

Southern Surgical Hospital, a hospital based in Louisiana, entered into an agreement to lease and utilize a Senhance Surgical System

●

First pediatric cases utilizing Senhance completed in October, representing the first time that 3mm instruments were used in robotic pediatric surgery

●

First surgical procedures successfully completed using the Intelligent Surgical Unit™ (ISU™), leveraging augmented intelligence and machine vision capabilities on the Senhance Surgical System

Year-End Highlights

●

In 2020, ten Senhance Systems were installed under operating leases, nine clinical programs were initiated, and over 1,450 procedures were performed globally

●

At December 31, 2020, the Company had approximately $17.5 million in cash, cash equivalents and restricted cash. The Company currently expects to have cash to support operations into the third quarter of 2021

●

Fourth quarter revenue is expected to be approximately $1.1 million

●

Full year 2020 revenue is expected to be approximately $3.0 - $3.2 million

“Looking at 2020 as a whole we are pleased with the momentum generated across our organization during these challenging times. We continued to expand our global footprint with new system installations and procedure volumes rebounded in the back half of the year across each of our geographies. In addition, we had a number of regulatory and portfolio expansion milestones including the introduction of machine vision and augmented intelligence which enable the promise of digital laparoscopy,” said Anthony Fernando, President and CEO of TransEnterix. "We built a great foundation in 2020 and we are planning to continue to execute on our strategy in 2021, bringing transformative technology to surgeons, hospitals and patients across the globe.”

Upcoming 2021 Milestones

During the first half of 2021, the Company expects to achieve the following regulatory milestones:

●

Receive CE Mark approval for the ISU in Europe

●

Receive FDA 510(k) clearance for General Surgery indication expansion

●

File for FDA 510(k) clearance for articulating instruments

●

File for FDA 510(k) clearance for the next generation ISU features

During the first half of 2021, the Company expects to publish clinical papers in peer reviewed journals on the following subjects:

●

Health economic studies comparing Senhance Digital Laparoscopy, laparoscopy, and robotic surgery

●

Clinical performance when utilizing the Senhance Surgical System

●

Operating room efficiency and surgeon ergonomics when utilizing Senhance Surgical System

Market Development

2020 Senhance Surgical System Placements

Throughout 2020, the Company initiated ten clinical programs: three in the US, four in Europe, and three in Asia.

In December 2020, the Company announced that Southern Surgical Hospital, a hospital based in Louisiana, has signed an agreement to initiate a Senhance Digital Laparoscopic program. This will represent the third Senhance Surgical program initiated in the state of Louisiana since 2018 (May 2018 - LSU Health’s University Medical Center New Orleans, January 2020 - Ochsner Baptist Medical Center). LSU Health, in addition to utilizing a Senhance system in their Digital Laparoscopy program, is home to one of the Senhance Surgical training centers in the southeast United States.

Training Sites

In the third quarter, the Company established the first training center for the Senhance Surgical System in the Asia-Pacific region in Japan at the Saitama Medical University International Medical Center in the Greater Tokyo Area. The Asia-Pacific region has been a major contributor of new system placements and surgical cases utilizing the Senhance Surgical System and the Asia-Pacific laparoscopy device market is expected to grow from $1.26 billion in 2019 to $1.87 billion by 2024, according to Market Data Forecast, Inc. The training center is expected to drive increased utilization of our eight system installations in the Asia-Pacific region and encourage further adoption of our technology in additional hospitals.

Procedure Volumes

In 2020, surgeons performed over 1,450 procedures utilizing the Senhance Surgical System, representing a 10% decrease over the previous year, which was less than our goal as a result of the COVID-19 pandemic. These procedures included general surgery, gynecology, urology, colorectal and bariatric surgical cases.

Foundational Sites

As of December 31, 2020, the Company had 11 foundational sites, up from 7 at the start of 2020. Foundational sites are hospitals that are performing clinical procedures with the Senhance Surgical System at an annualized rate of greater than 100 procedures per year.

Clinical Validation

During 2020, there were 15 peer-reviewed clinical papers published providing further support of the clinical utility of the Senhance Surgical System across gynecology, general surgery, urology and colorectal procedures demonstrating the utility breadth and the complexity of procedures being performed.

Portfolio Expansion

Intelligent Surgical Unit™(ISU™)

The Company received 510(k) clearance for the ISU that enables machine vision capabilities on the Senhance Surgical System. On September 23, 2020, the Company announced the first surgical procedures successfully completed using the ISU.

Pediatric Indication

The Company received CE Mark approval for an expanded indication to treat pediatric patients. During the fourth quarter of 2020, the Company announced the first pediatric surgical cases with Senhance Surgical System at Maastricht University Medical Center+ in the Netherlands.

General Surgery Indication

The Company submitted an application for 510(k) approval for an expanded General Surgery indication for use for the Senhance Surgical System to the FDA.

Russian Regulatory Approval

During the fourth quarter of 2020, the Company received approval for the Senhance Surgical System in the Russian Federation allowing for its sale and utilization throughout the Russian Federation. We believe that the Russian robotic surgery market is underserved and provides an opportunity to grow Senhance Surgical System placements and sales.

Fourth Quarter and Full Year 2020 Revenue

During the quarter ended December 31, 2020, the Company expects preliminary unaudited revenue of approximately $1.1 million. For the full year, preliminary unaudited 2020 revenue is expected to be approximately $3.0 - $3.2 million, representing revenues from Senhance Surgical System leasing and related revenues from instruments, accessories and services.

Balance Sheet

As of December 31, 2020, the Company had preliminary unaudited cash, cash equivalents and restricted cash of approximately $17.5 million, and there were approximately 116.2 million shares of common stock outstanding.

On October 9, 2020, the Company filed a prospectus supplement, relating to an “at the market” offering (ATM Offering) of up to an aggregate of $40.0 million of shares of the Company’s common stock, through Cantor Fitzgerald & Co. (Cantor), as sales agent under an existing Sales Agreement. During the quarter ended December 31, 2020, the Company raised gross proceeds of approximately $9.3 million, and net proceeds of approximately $9.0 million under the ATM Offering.

As a result of the restructuring completed in the first quarter of 2020, cost optimization efforts, and equity financings, together with anticipated cash received from operating activities, including cash from system sales and leases, instruments and accessories, and services, we believe that cash on hand will be sufficient to meet our anticipated cash needs into the third quarter of 2021.

COVID-19 Pandemic

The COVID-19 pandemic continues to have a significant impact on the Company’s operations, primarily due to the temporary cessation of elective surgical procedures in many markets, and the challenges and restrictions caused by stay-at-home orders, social distancing requirements and travel restrictions. The Company’s business and customers were negatively impacted by the COVID-19 pandemic, which suspended many elective surgical procedures globally, curtailed travel and necessarily diverted the attention of hospital customers. The Company has taken steps, and continues to take further actions, to minimize the impact of the COVID-19 pandemic on its business. A variety of travel restrictions have caused delays in product installation and training activities. Since the second quarter of 2020, the Company has seen elective surgical procedures recommence in the United States, Europe and Japan, but not, to date, to the levels seen before the COVID-19 pandemic. This has significantly impacted its ability to implement its market development activities to place its Senhance Systems, provide training, and increase the use of the Senhance Systems in place. Given the dynamic nature of this health emergency, the full impact of the COVID-19 pandemic on ongoing business, results of operations and overall financial performance cannot be reasonably estimated at this time.

About TransEnterix

At TransEnterix, Inc., we are digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through a new category of care called Digital Laparoscopy. Digitizing the interface enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and allows us to address the current clinical, cognitive and economic shortcomings in surgery. The system features the first machine vision system for use in robotic surgery which is powered by the new Intelligent Surgical Unit™ (ISU™) that enables augmented intelligence in surgery. The Senhance Surgical System brings the benefits of Digital Laparoscopy to patients around the world while staying true to the principles of value-based healthcare. Learn more about Digital Laparoscopy with the Senhance Surgical System here: https://Senhance.com/. Now available for sale in the US, the EU, Japan, Russia, and select other countries. For a complete list of indications for use, please visit: https://www.transenterix.com/indications-for-use/.

Forward-Looking Statements

This press release includes statements relating to the Senhance System and our preliminary 2020 results. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether we will be able to continue to progress our strategic plan in 2021; whether 2020 fourth quarter revenue will be approximately $1.1 million; whether 2020 revenue for the full year will be approximately $3.0 - $3.2 million; whether cash, cash equivalents and restricted cash will be $17.5 million as of December 31, 2020; whether the Russian robotic surgery market is underserved and provides an opportunity to grow Senhance Surgical System placements and sales; whether we can continue to increase Senhance System placements and sales, whether we can continue to add foundational sites and receive regulatory clearances and approvals that we seek, whether our cash on hand will be sufficient to meet our anticipated cash needs into the third quarter of 2021 and whether we can continue to support our operations through capital raising transactions. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For TransEnterix, Inc.

Investor Contact:

Mark Klausner, +1 443-213-0501

invest@transenterix.com

Media Contact:

Terri Clevenger, +1 203-682-8297

terri.clevenger@icrinc.com

EX-101.SCH 3 trxc-20210106.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 trxc-20210106_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 trxc-20210106_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 trxc-20210106_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 transe20210105_8k_htm.xml IDEA: XBRL DOCUMENT 0000876378 2021-01-06 2021-01-06 false 0000876378 8-K 2021-01-06 TransEnterix, Inc. DE 0-19437 11-2962080 635 Davis Drive Suite 300 Morrisville NC 27560 919 765-8400 false false false false Common Stock TRXC NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Jan. 06, 2021
Document Information [Line Items]
Entity, Registrant Name	TransEnterix, Inc.
Document, Type	8-K
Document, Period End Date	Jan. 06, 2021
Entity, Incorporation, State or Country Code	DE
Entity, File Number	0-19437
Entity, Tax Identification Number	11-2962080
Entity, Address, Address Line One	635 Davis Drive
Entity, Address, Address Line Two	Suite 300
Entity, Address, City or Town	Morrisville
Entity, Address, State or Province	NC
Entity, Address, Postal Zip Code	27560
City Area Code	919
Local Phone Number	765-8400
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	TRXC
Security Exchange Name	NYSE
Entity, Emerging Growth Company	false
Amendment Flag	false
Entity, Central Index Key	0000876378

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.trxc.com/20210106/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports transe20210105_8k.htm ex_219892.htm trxc-20210106.xsd trxc-20210106_def.xml trxc-20210106_lab.xml trxc-20210106_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "transe20210105_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "trxc-20210106_def.xml" ] }, "inline": { "local": [ "transe20210105_8k.htm" ] }, "labelLink": { "local": [ "trxc-20210106_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "trxc-20210106_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "trxc-20210106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "trxc", "nsuri": "http://www.trxc.com/20210106", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "transe20210105_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.trxc.com/20210106/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "transe20210105_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity, Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.trxc.com/20210106/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001437749-21-000199-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-000199-xbrl.zip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end